Retinal vein occlusion Treatment

Anti-VEGF Injections

One of the most commonly used treatments involves injections of medications called anti-VEGF drugs directly into the eye. VEGF stands for vascular endothelial growth factor, which is a protein that the eye produces when it doesn't get enough oxygen. Too much VEGF causes blood vessels to leak fluid and can trigger the growth of abnormal blood vessels.4 Anti-VEGF medications work by blocking this protein, which helps reduce swelling and prevent the formation of problematic new blood vessels.

These medications are delivered through intravitreal injections, meaning they are injected directly into the vitreous, the gel-like substance that fills the eye.5 Common anti-VEGF drugs used for this condition include ranibizumab, aflibercept, and bevacizumab.6 Clinical trials have shown that anti-VEGF therapy is safe and effective over two years for treating macular edema caused by retinal vein occlusion, and research indicates that delaying treatment can lead to worse outcomes for vision.6

Patients typically need multiple injections over time, as the effects of each injection wear off after several weeks or months. The exact number and frequency of injections varies depending on how the eye responds to treatment. While the idea of having injections in the eye may sound uncomfortable, doctors use numbing drops to minimize discomfort, and the procedure is relatively quick.5

Corticosteroid Treatments

Steroid medications are another treatment option for managing macular edema in retinal vein occlusion. These drugs work by reducing inflammation and decreasing the production of VEGF, which helps stabilize blood vessels and reduce fluid leakage.6 Two main corticosteroid preparations are used: triamcinolone acetonide and dexamethasone.

The SCORE (Standard Care vs Corticosteroid for Retinal Vein Occlusion) study, sponsored by the National Eye Institute, compared different doses of triamcinolone injected into the eye versus observation alone. The study found that intravitreal triamcinolone provided better visual outcomes over 12 months than observation, though the benefits diminished after the first year.6

Dexamethasone is available as an intravitreal implant, which is a tiny device that slowly releases the medication over several months.6 This approach can reduce the number of injections needed compared to anti-VEGF therapy. However, corticosteroids carry a higher risk of side effects, including increased eye pressure that can lead to glaucoma, and cataract formation.6 The American Academy of Ophthalmology has reported that while intravitreal corticosteroid therapy shows short-term effectiveness, it is associated with more frequent adverse events compared to anti-VEGF therapy.6

Laser Photocoagulation

Laser treatment plays an important role in managing certain complications of retinal vein occlusion, particularly in preventing and treating neovascularization. Panretinal photocoagulation involves applying laser burns to the peripheral parts of the retina to reduce the eye's oxygen demand and prevent the growth of abnormal blood vessels that can lead to a severe form of glaucoma.7

The timing and indications for laser treatment remain somewhat controversial. The Central Vein Occlusion Study recommended careful observation of ischemic cases, with laser treatment applied immediately after abnormal blood vessels develop in the iris, angle, or retina.7 However, some specialists prefer to apply laser treatment earlier in severely ischemic cases, which can be identified by the presence of multiple cotton wool spots (areas of damaged retina) or extensive areas where blood no longer flows.7

Focal laser treatment may also be used specifically to target areas of macular edema, though this approach has largely been replaced by injection therapies in recent years.2 The laser creates small burns that help seal leaking blood vessels and reduce fluid accumulation.

Managing Underlying Health Conditions

A critical component of standard treatment involves controlling the health conditions that contributed to the retinal vein blockage. Managing high blood pressure is particularly important, as uncontrolled hypertension is a major risk factor for retinal vein occlusion.2 Patients with diabetes need to maintain good blood sugar control to reduce the risk of complications and prevent the condition from affecting the other eye.

Some doctors may recommend aspirin or other blood thinners to help prevent new blockages, though evidence for this approach varies.2 Lifestyle modifications such as eating a low-fat diet, getting regular exercise, maintaining a healthy weight, and stopping smoking are all measures that can decrease the risk of retinal vein occlusion and other blood vessel diseases.2

Duration of Treatment

The duration of treatment for retinal vein occlusion varies considerably from person to person. Many patients require ongoing treatment for months or years, especially when dealing with persistent macular edema. Patients receiving anti-VEGF injections typically need treatment every 4 to 8 weeks initially, with the possibility of extending the interval between injections if the condition stabilizes.6

Regular monitoring appointments are essential even after active treatment ends, as complications such as glaucoma can develop three or more months after the initial blockage.2 Eye care specialists use various imaging tests during these follow-up visits to check for signs of swelling or abnormal blood vessel growth that might require resuming treatment.

Advanced Anti-VEGF Molecules

Clinical trials are testing newer anti-VEGF medications that may last longer in the eye, potentially reducing the number of injections patients need. These next-generation molecules are designed to bind more tightly to VEGF or to target multiple growth factors simultaneously, which could provide more complete control of macular edema and abnormal blood vessel growth.

The specific mechanisms of action for these experimental drugs often involve blocking not just VEGF but also related proteins that contribute to blood vessel leakage and inflammation. By targeting multiple pathways at once, researchers hope to achieve better vision outcomes and longer-lasting effects from each injection.

Novel Drug Delivery Systems

One major focus of clinical research involves developing better ways to deliver medications to the eye without requiring frequent injections. Researchers are testing sustained-release implants that can slowly release anti-VEGF drugs or other medications over several months. These implants, which are much smaller than a grain of rice, are placed inside the eye during a minor surgical procedure and can potentially eliminate the need for monthly injections.

Some clinical trials are also investigating refillable drug delivery devices that can be implanted in the eye and then refilled periodically through a simple office procedure, rather than requiring a new implant each time the medication runs out. These systems are still in early phases of testing, typically Phase I or Phase II trials, where researchers are primarily evaluating safety and determining the optimal dosing schedules.

Combination Therapies

Clinical trials are exploring whether combining different types of treatments might work better than using any single therapy alone. For example, some studies are testing whether using anti-VEGF injections together with corticosteroids provides better control of macular edema than either treatment by itself. The rationale is that these medications work through different mechanisms, so using them together might address more aspects of the disease process.

Other combination approaches being studied include pairing anti-VEGF therapy with medications that target inflammation or that strengthen the blood-retina barrier to prevent fluid leakage. Early results from some of these trials have shown promise, with some patients experiencing greater improvements in vision or needing fewer treatments when receiving combination therapy.

Tissue Plasminogen Activator

Some clinical trials have investigated injecting tissue plasminogen activator (tPA) directly into the eye. This medication is a clot-dissolving drug that works by breaking down blood clots. The theory is that tPA might help dissolve the clot blocking the retinal vein or clear hemorrhages that develop as a result of the blockage.6

However, results from trials testing intravitreal tPA have been mixed, and this approach has not become a standard treatment. The challenges include determining the right dose, timing the injection appropriately, and managing potential side effects. Research in this area continues, as scientists work to identify which patients might benefit most from this approach and how to optimize the treatment protocol.

Experimental Surgical Approaches

Some clinical trials have explored surgical techniques aimed at relieving the compression that causes retinal vein occlusion or improving blood flow to the retina. These experimental procedures, which are typically tested in Phase I or Phase II trials, involve delicate operations on the tiny blood vessels of the eye. While some early studies showed potential promise, surgical approaches have not been widely adopted due to risks and variable outcomes.6

Pars plana vitrectomy, a surgery to remove the vitreous gel from the eye, has been studied as a potential treatment that might improve medication delivery to the retina or help remove blood and scar tissue.7 However, this remains an investigational approach primarily reserved for complex cases or research settings.

Geographic Availability of Clinical Trials

Clinical trials for retinal vein occlusion treatments are conducted at major medical centers and research institutions around the world, including in the United States, Europe, and other regions. Eligibility for these trials typically depends on factors such as the type and severity of retinal vein occlusion, how recently the blockage occurred, the level of vision remaining, and whether the patient has other eye conditions or health problems that might affect the study results.

The National Eye Institute and other government agencies sponsor some of these trials, while pharmaceutical and medical device companies fund others. Patients can search for relevant clinical trials through registries maintained by government health agencies or by asking their eye care specialist about available studies in their area.